Saltar al contenido
PivotalWire
Domingo 11 oct 2026SEC · NASDAQ biomédico

Portada›Viernes 2 de enero de 2026

Biomédicas del NASDAQ ante la SEC, viernes 2 de enero de 2026

Los 32 documentos que 30 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.

·

El día, bloque a bloque

Va en color lo que cambia el capital o avisa de un riesgo: las emisiones con precio (424B1, 424B2, 424B4 y 424B5), los 8-K con item 1.02, 1.03, 2.04, 3.01, 3.02 y 4.02, y cualquier documento en el que haya aparecido una frase vigilada, que va citada debajo. Lo demás va en tinta normal. Una cita marcada «por primera vez» es una frase que no estaba en el informe previo del mismo tipo de esa empresa. La etiqueta del formulario lleva a su explicación.

Emisiones y dilución

  1. ISPCiSpecimen Inc.424B3Prospecto suplementario o de reventaEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…profitability in subsequent periods. Our prior losses and expected future losses have had and will continue to have adverse effects on our stockholders’ equity (deficit) and working capital. There is substantial doubt about our ability to continue as a going concern. Our audited financial statements included in this Annual Report include an explanatory paragraph that indicates that they were prepared assuming that we would continue as a going concern. We have suffered…
    En el documentoDebilidad material en el control internotexto original ▸…recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. During the year ended December 31, 2024, we identified a material weakness in our internal control over financial reporting that may cause us to fail to meet our reporting obligations or result in material misstatements of our financial statements. If we fail to remediate this…
  2. MDCXMedicus Pharma Ltd.424B5Nueva emisión de acciones con precioEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…EisnerAmper LLP, independent registered public accounting firm, as stated in their report which is incorporated by reference herein which report includes an explanatory paragraph about the existence of substantial doubt concerning the Company's ability to continue as a going concern. Such financial statements have been incorporated by reference herein in reliance on the report of such firm given upon their authority as experts in accounting and auditing. The consolidated balance…
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸424B5 1 form424b5.htm FORM 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-292475 PROSPECTUS SUPPLEMENT (To Prospectus dated December 29, 2025) Up to $15,349,674 Common Shares We have entered into an At the Market Offering Sales Agreement dated as of December 29, 2025 (the “sales agreement”) with Maxim Group LLC (“Maxim”) and Yorkville Securities, LLC (“Yorkville”) (each of Maxim and Yorkville individually an “Agent” and…
  3. CVKDCadrenal Therapeutics, Inc.424B3Prospecto suplementario o de reventaEDGAR
  4. PVLAPALVELLA THERAPEUTICS, INC.S-3Capacidad de emisión registradaEDGAR

Participaciones y control

  1. INABIN8BIO, INC.SC 13DCambio en participación significativaEDGAR
  2. MGTXMeiraGTx Holdings plcSC 13D/ACambio en participación significativaEDGAR
  3. PCRXPacira BioSciences, Inc.SC 13D/ACambio en participación significativaEDGAR
  4. ZNTLZentalis Pharmaceuticals, Inc.SC 13D/ACambio en participación significativaEDGAR

Informes y hechos relevantes

  1. CDTCDT Equity Inc.8-KVenta de acciones no registrada (colocación privada)EDGAR
  2. CINGCingulate Inc.8-KVenta de acciones no registrada (colocación privada)EDGAR
  3. DCOYDecoy Therapeutics Inc.8-KAviso de incumplimiento de cotizaciónEDGAR
    En el documentoContrasplit de accionestexto original ▸…(3)(A)(iv) and the Company remaining subject to a Mandatory Panel Monitor, the Company is not eligible for any compliance period specified in Nasdaq listing rule 5810(c)(3)(A) because the Company has effected a reverse stock split during the prior one-year period. Accordingly, unless the Company requests an appeal of the delisting determination by January 7, 2026, Nasdaq has determined that the Company’s securities will be scheduled…
  4. ELDNEledon Pharmaceuticals, Inc.8-KVenta de acciones no registrada (colocación privada)EDGAR
  5. ELUTELUTIA INC.8-KAviso de incumplimiento de cotizaciónEDGAR
  6. FBLGFibroBiologics, Inc.8-KAviso de incumplimiento de cotizaciónEDGAR
  7. ISPCiSpecimen Inc.8-KVenta de acciones no registrada (colocación privada)EDGAR
  8. RANIRani Therapeutics Holdings, Inc.8-KFin de acuerdo materialEDGAR
  9. RNXTRenovoRx, Inc.8-KAviso de incumplimiento de cotizaciónEDGAR
  10. ZURAZura Bio Ltd8-KFin de acuerdo materialEDGAR
  11. ALMSALUMIS INC.8-KOtros hechos relevantesEDGAR
  12. ATRAAtara Biotherapeutics, Inc.8-KNuevo acuerdo materialEDGAR
  13. GNLXGENELUX Corp8-KCambio en el consejo o la direcciónEDGAR
    En el documentoCambio en la dirección de la empresatexto original ▸…Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Principal Officer or Named Executive Officer On December 30, 2025, Paul Scigalla, M.D. resigned as Chief Medical Officer of Genelux Corporation (the “Company”), effective immediately. Appointment of Jason Litten, M.D. as Chief Medical Officer On January 2, 2026, the Company announced the appointment of Jason Litten, M.D…
  14. INDPIndaptus Therapeutics, Inc.8-KCambio en el consejo o la direcciónEDGAR
  15. INKTMiNK Therapeutics, Inc.8-KCambio en el consejo o la direcciónEDGAR
  16. IRWDIRONWOOD PHARMACEUTICALS INC8-KResultadosEDGAR
  17. KALAKALA BIO, Inc.8-KOtros hechos relevantesEDGAR
  18. MGTXMeiraGTx Holdings plc8-KNuevo acuerdo materialEDGAR
  19. OTLKOutlook Therapeutics, Inc.8-KOtros hechos relevantesEDGAR
  20. TNYATenaya Therapeutics, Inc.8-KCambio en el consejo o la direcciónEDGAR
  21. VORVor Biopharma Inc.8-KCambio en el consejo o la direcciónEDGAR

Juntas de accionistas

  1. MBRXMoleculin Biotech, Inc.DEF 14AConvocatoria de junta de accionistasEDGAR
  2. ONCOOnconetix, Inc.DEF 14AConvocatoria de junta de accionistasEDGAR
    En el documentoContrasplit de accionestexto original ▸…unanimously determined and resolved that the Reverse Stock Split Proposal and the Adjournment Proposal are advisable and fair to, and in the best interests of, Onconetix and its stockholders, and has approved the Reverse Stock Split Amendment, subject to stockholder approval. Accordingly, the Onconetix Board unanimously recommends that Onconetix stockholders vote “FOR” each of the foregoing proposals. Your vote is important. More…
  3. RLYBRallybio CorpDEF 14AConvocatoria de junta de accionistasEDGAR
    En el documentoContrasplit de accionestexto original ▸…contains approximate information, based on share information as of December 19, 2025 relating to our outstanding common stock based on the proposed reverse stock split ratios assuming that the proposal is approved and the reverse stock split is implemented. Status Number of Shares of Common Stock Authorized Number of Shares of Common Stock Issued and Outstanding Number of Shares of Common Stock Authorized but Not Outstanding Pre-Reverse Stock…

·

Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.